Christian Schultheis | University of Iowa Clinical Research and Trials

Attention Site Visitor

You are currently visiting the UI Health Care Clinical Trials website on a version of the web browser: Internet Explorer. Internet Explorer is no longer being supported by Microsoft, and there are features and functionality on this website that does not operate properly when using Internet Explorer. If you have an alternative browser, such as: Microsoft Edge, Google Chrome, Mozilla Firefox, or Apple Safari, we suggest you switch to that browser for the optimal viewing experience.

Thank you

Studies

Mission: A Phase 2/3, Randomized, Double-blind, Controlled Study of Zanzalintinib (XL092) in Combination with Pembrolizumab vs Pembrolizumab in the First-line Treatment of Subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell…

Cancer Internal Medicine Head and Neck Cancer Skin Cancer Adult Subjects

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.